Research shows that an increasing number of adults are experiencing pneumococcal pneumonia. In adults, the same bacteria that causes the condition can also “invade” other areas of the body that are normally free from germs. When this happens, it can affect the blood, as well as the lining of the brain and spinal cord. This educational session provides an overview of a preventative vaccine available for both pediatric and adult populations.

As a result of participating in this session, attendees will be able to:

• Discuss the ongoing burden and shifting epidemiology of pneumococcal disease in adults
• Review the robust clinical trial program for an option to help address IPD in adults
• Highlight the 2024 CDC recommendations for adult pneumococcal disease

Presented by Reena Gulati, MD, MPH, Regional Medical Director, Merck & Co., Inc

Complimentary for CCALAC Members and Affiliates

Register Now!

Instructor Biography:

Reena Gulati, MD, MPH, is a Regional Medical Director employed by Merck & Co., Inc. In addition to her roles in vaccine development with the HIV Vaccine Trials Network and the Bill & Melinda Gates Foundation, she spent nearly a decade with the Centers for Disease Control and Prevention focusing on the prevention and response to vaccine-preventable diseases. Dr. Gulati graduated from Stanford University, earned her MD from Oregon Health & Science University, completed her internal medicine training and chief residency at Stanford University Hospital, and her infectious disease fellowship and MPH from the University of Washington. Dr. Gulati is board-certified in both internal medicine and infectious diseases.